Premium – Page 21 – Endpoints News

SIGN UP

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

5 years ago

By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?

5 years ago

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management

5 years ago

Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records

5 years ago

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

5 years ago

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

5 years ago

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

5 years ago

The Great Pharma Brexit? An Endpoints News snap poll finds most life sciences insiders predicting a debacle for the industry

5 years ago

Winners and losers at #ESMO18

5 years ago

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

5 years ago

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

5 years ago

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

5 years ago

Global reach: The top 25 biopharma companies in the world

5 years ago

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

5 years ago

The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the deal table?

5 years ago

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

5 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2018

5 years ago

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?

5 years ago

12 top China VCs you need to know who are making a transpacific splash (Part 2)

5 years ago

RIP XTuit: Great brains, hot target and vet CEO Deborah Dunsire in charge couldn’t stop this biotech from going down

5 years ago

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

5 years ago

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

5 years ago

Where does the science come from? The top 20 NIH-funded institutions in 2017

5 years ago

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

5 years ago

First page Previous page 18 19 202122 Next page Last page